Ipamorelin 5mL x 2 vials
Ipamorelin 5mL x 2 vialsPotency: 2000mcg/ml
Delivered As: 5mL x 2 vials
ProtocolContent and Potency: 5mL x 2 vials at 2000mcg/ml ready-to-inject subcutaneous Suggested dosage: 0.1ml twice daily or 0.2ml at night before bed on an empty stomach for 5 days out of 7
Description-Ipamorelin is a selective GH-Secretagogue and ghrelin receptor agonist. The potency of ghrelin stimulation can be compared to GHRP6 with less appetite stimulation properties. However, unlike other GH-Secretagogues this pentapeptide doesn’t release the same volumes of cortisol, acetylcholine, prolactin and aldosterone. It is for this reason Ipamorelin has been considered the first selective GH-Secretagogue.
Clinical Research-‘Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.’ – Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Source: Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, USA Purpose: To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers. Methods: A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level. Concentrations of ipamorelin and growth hormone were measured. Results: The PK parameters showed dose-proportionality, with a short terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady-state of 0.22 L/kg. The time course of GH stimulation by ipamorelin showed a single episode of GH release with a peak at 0.67 hours and an exponential decline to negligible GH concentration at all doses. The ipamorelin-GH concentration relationship was characterized using an indirect response model and population fitting. The model employed a zero-order GH release rate over a finite duration of time to describe the episodic release of GH. Ipamorelin induces the release of GH at all dose levels with the concentration (SC50) required for half-maximal GH stimulation of 214 nmol/L and a maximal GH production rate of 694 mIU/L/h. The inter-individual variability of the PD parameters was larger than that of the PK parameters. Conclusions: The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses. A full copy of all trials are available from PeptidesOnline. Please contact us for more information.
Protocol-Content and Potency: 5mL x 2 vials at 2000mcg/ml ready-to-inject subcutaneous Suggested dosage: 0.1ml twice daily or 0.2ml at night before bed on an empty stomach for 5 days out of 7 Please note, as this is a prescription item, one of our doctors will review your profile and approve your order if appropriate. A prescription will only be issued in accordance to the prescribing guidelines, and for use that strictly complies to the doctor’s directions and dosage. This script will be forwarded to our dispensary team, and placed in our secure, internal records.